Monoclonal antibodies “for use in SubB2M immunoassays”, a vague description and in typical style of this management. Is it not the big advantage of SuB2M (and the licensed IP) that it is a specific ligand that can detect the Neu5Gc better than antibodies against Neu5Gc? If that is so, what are the antibodies directed against? Against the SubB2M? If so, does this mean that the CA125/SubB2M ELIZA does not work as promisingly as announced on 17 August 2021?
Ann: INOVIQ Awarded Additional BTB Funding to Develop SubB2M test, page-17
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.18M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.0¢ | 45.0¢ | $6.16K | 13.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42909 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 6850 | 1 |
View Market Depth
| Last trade - 13.26pm 11/11/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |